nodes	percent_of_prediction	percent_of_DWPC	metapath
Reboxetine—SLC6A4—chronic obstructive pulmonary disease	0.492	1	CbGaD
Reboxetine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0475	0.147	CbGbCtD
Reboxetine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0475	0.147	CbGbCtD
Reboxetine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0424	0.131	CbGbCtD
Reboxetine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0399	0.124	CbGbCtD
Reboxetine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0269	0.0835	CbGbCtD
Reboxetine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0257	0.0797	CbGbCtD
Reboxetine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0229	0.071	CbGbCtD
Reboxetine—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0224	0.0695	CbGbCtD
Reboxetine—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0212	0.0657	CbGbCtD
Reboxetine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0134	0.0417	CbGbCtD
Reboxetine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0127	0.0393	CbGbCtD
Reboxetine—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00102	0.0546	CbGpPWpGaD
Reboxetine—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.000901	0.0482	CbGpPWpGaD
Reboxetine—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.000737	0.0394	CbGpPWpGaD
Reboxetine—HTR2C—Serotonin receptors—HTR2A—chronic obstructive pulmonary disease	0.00049	0.0262	CbGpPWpGaD
Reboxetine—SLC6A2—Monoamine Transport—SLC6A4—chronic obstructive pulmonary disease	0.000452	0.0242	CbGpPWpGaD
Reboxetine—SLC6A4—Serotonin Transporter Activity—IL1B—chronic obstructive pulmonary disease	0.000449	0.024	CbGpPWpGaD
Reboxetine—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000374	0.02	CbGpPWpGaD
Reboxetine—Atomoxetine—SLC6A4—chronic obstructive pulmonary disease	0.000367	0.299	CrCbGaD
Reboxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—chronic obstructive pulmonary disease	0.000326	0.0174	CbGpPWpGaD
Reboxetine—Phenprocoumon—ALB—chronic obstructive pulmonary disease	0.000309	0.251	CrCbGaD
Reboxetine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000295	0.0158	CbGpPWpGaD
Reboxetine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000292	0.00176	CcSEcCtD
Reboxetine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000291	0.00176	CcSEcCtD
Reboxetine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000289	0.00175	CcSEcCtD
Reboxetine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000289	0.00175	CcSEcCtD
Reboxetine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000289	0.00175	CcSEcCtD
Reboxetine—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00174	CcSEcCtD
Reboxetine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000287	0.0153	CbGpPWpGaD
Reboxetine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00173	CcSEcCtD
Reboxetine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00173	CcSEcCtD
Reboxetine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000286	0.00173	CcSEcCtD
Reboxetine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.00173	CcSEcCtD
Reboxetine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000285	0.00172	CcSEcCtD
Reboxetine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000283	0.00171	CcSEcCtD
Reboxetine—Atomoxetine—HTR2A—chronic obstructive pulmonary disease	0.000282	0.23	CrCbGaD
Reboxetine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000281	0.0017	CcSEcCtD
Reboxetine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000281	0.0017	CcSEcCtD
Reboxetine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000281	0.0017	CcSEcCtD
Reboxetine—HTR2C—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000279	0.0149	CbGpPWpGaD
Reboxetine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000278	0.00168	CcSEcCtD
Reboxetine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000276	0.00167	CcSEcCtD
Reboxetine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000275	0.00166	CcSEcCtD
Reboxetine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000275	0.00166	CcSEcCtD
Reboxetine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000273	0.00165	CcSEcCtD
Reboxetine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00165	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000272	0.00164	CcSEcCtD
Reboxetine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000271	0.00163	CcSEcCtD
Reboxetine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00027	0.00163	CcSEcCtD
Reboxetine—Diphenhydramine—CYP1A2—chronic obstructive pulmonary disease	0.00027	0.22	CrCbGaD
Reboxetine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00027	0.00163	CcSEcCtD
Reboxetine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00163	CcSEcCtD
Reboxetine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00163	CcSEcCtD
Reboxetine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000266	0.0016	CcSEcCtD
Reboxetine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.0016	CcSEcCtD
Reboxetine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000265	0.0016	CcSEcCtD
Reboxetine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.0016	CcSEcCtD
Reboxetine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000264	0.0016	CcSEcCtD
Reboxetine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.0016	CcSEcCtD
Reboxetine—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.0016	CcSEcCtD
Reboxetine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000264	0.0016	CcSEcCtD
Reboxetine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000264	0.0016	CcSEcCtD
Reboxetine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.0016	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.00159	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000264	0.00159	CcSEcCtD
Reboxetine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00158	CcSEcCtD
Reboxetine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00158	CcSEcCtD
Reboxetine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00157	CcSEcCtD
Reboxetine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00026	0.00157	CcSEcCtD
Reboxetine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00026	0.00157	CcSEcCtD
Reboxetine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000259	0.00157	CcSEcCtD
Reboxetine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00156	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000258	0.00156	CcSEcCtD
Reboxetine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000258	0.00156	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000258	0.0138	CbGpPWpGaD
Reboxetine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.00154	CcSEcCtD
Reboxetine—Infection—Formoterol—chronic obstructive pulmonary disease	0.000253	0.00153	CcSEcCtD
Reboxetine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.00153	CcSEcCtD
Reboxetine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.00151	CcSEcCtD
Reboxetine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00025	0.00151	CcSEcCtD
Reboxetine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00151	CcSEcCtD
Reboxetine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00151	CcSEcCtD
Reboxetine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00151	CcSEcCtD
Reboxetine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000249	0.00151	CcSEcCtD
Reboxetine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000248	0.0015	CcSEcCtD
Reboxetine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.0015	CcSEcCtD
Reboxetine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.0015	CcSEcCtD
Reboxetine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000248	0.0015	CcSEcCtD
Reboxetine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000247	0.00149	CcSEcCtD
Reboxetine—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000247	0.0132	CbGpPWpGaD
Reboxetine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00149	CcSEcCtD
Reboxetine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00149	CcSEcCtD
Reboxetine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000246	0.00149	CcSEcCtD
Reboxetine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00148	CcSEcCtD
Reboxetine—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000245	0.00148	CcSEcCtD
Reboxetine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000244	0.00148	CcSEcCtD
Reboxetine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000242	0.00146	CcSEcCtD
Reboxetine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000241	0.00146	CcSEcCtD
Reboxetine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00144	CcSEcCtD
Reboxetine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000238	0.00144	CcSEcCtD
Reboxetine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000238	0.00144	CcSEcCtD
Reboxetine—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000238	0.0127	CbGpPWpGaD
Reboxetine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00143	CcSEcCtD
Reboxetine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00142	CcSEcCtD
Reboxetine—HTR2C—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000235	0.0126	CbGpPWpGaD
Reboxetine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00142	CcSEcCtD
Reboxetine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00141	CcSEcCtD
Reboxetine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000232	0.0014	CcSEcCtD
Reboxetine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.0014	CcSEcCtD
Reboxetine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.00139	CcSEcCtD
Reboxetine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00023	0.00139	CcSEcCtD
Reboxetine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.00138	CcSEcCtD
Reboxetine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000229	0.00138	CcSEcCtD
Reboxetine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00137	CcSEcCtD
Reboxetine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00137	CcSEcCtD
Reboxetine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000226	0.00137	CcSEcCtD
Reboxetine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000226	0.00137	CcSEcCtD
Reboxetine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000225	0.00136	CcSEcCtD
Reboxetine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00136	CcSEcCtD
Reboxetine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00135	CcSEcCtD
Reboxetine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00135	CcSEcCtD
Reboxetine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000224	0.00135	CcSEcCtD
Reboxetine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000222	0.0119	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000222	0.0119	CbGpPWpGaD
Reboxetine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00134	CcSEcCtD
Reboxetine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000221	0.00134	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00133	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00133	CcSEcCtD
Reboxetine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00133	CcSEcCtD
Reboxetine—HTR2C—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000218	0.0117	CbGpPWpGaD
Reboxetine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00131	CcSEcCtD
Reboxetine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00131	CcSEcCtD
Reboxetine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00131	CcSEcCtD
Reboxetine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.0013	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000215	0.0013	CcSEcCtD
Reboxetine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000215	0.0115	CbGpPWpGaD
Reboxetine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00129	CcSEcCtD
Reboxetine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00129	CcSEcCtD
Reboxetine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000213	0.00128	CcSEcCtD
Reboxetine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00128	CcSEcCtD
Reboxetine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00127	CcSEcCtD
Reboxetine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00127	CcSEcCtD
Reboxetine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.00021	0.00127	CcSEcCtD
Reboxetine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00021	0.00127	CcSEcCtD
Reboxetine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00021	0.00127	CcSEcCtD
Reboxetine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000209	0.00127	CcSEcCtD
Reboxetine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.00126	CcSEcCtD
Reboxetine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000208	0.00126	CcSEcCtD
Reboxetine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000208	0.00126	CcSEcCtD
Reboxetine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000208	0.00126	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00125	CcSEcCtD
Reboxetine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00124	CcSEcCtD
Reboxetine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00123	CcSEcCtD
Reboxetine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.00122	CcSEcCtD
Reboxetine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000202	0.00122	CcSEcCtD
Reboxetine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000201	0.00122	CcSEcCtD
Reboxetine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000201	0.00122	CcSEcCtD
Reboxetine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.00122	CcSEcCtD
Reboxetine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.00122	CcSEcCtD
Reboxetine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.0002	0.00121	CcSEcCtD
Reboxetine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Reboxetine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Reboxetine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Reboxetine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Reboxetine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000198	0.0012	CcSEcCtD
Reboxetine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000198	0.0012	CcSEcCtD
Reboxetine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Reboxetine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Reboxetine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Reboxetine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Reboxetine—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Reboxetine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00119	CcSEcCtD
Reboxetine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000194	0.00117	CcSEcCtD
Reboxetine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000193	0.0103	CbGpPWpGaD
Reboxetine—SLC6A4—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000191	0.0102	CbGpPWpGaD
Reboxetine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00115	CcSEcCtD
Reboxetine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00115	CcSEcCtD
Reboxetine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00115	CcSEcCtD
Reboxetine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00113	CcSEcCtD
Reboxetine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00113	CcSEcCtD
Reboxetine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000187	0.00113	CcSEcCtD
Reboxetine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.00113	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000184	0.00983	CbGpPWpGaD
Reboxetine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00111	CcSEcCtD
Reboxetine—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000184	0.00982	CbGpPWpGaD
Reboxetine—HTR2C—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000183	0.00981	CbGpPWpGaD
Reboxetine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.0011	CcSEcCtD
Reboxetine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000183	0.0011	CcSEcCtD
Reboxetine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.00018	0.00109	CcSEcCtD
Reboxetine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.00018	0.00109	CcSEcCtD
Reboxetine—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00018	0.00961	CbGpPWpGaD
Reboxetine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Reboxetine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00107	CcSEcCtD
Reboxetine—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000176	0.00941	CbGpPWpGaD
Reboxetine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Reboxetine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Reboxetine—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000173	0.00924	CbGpPWpGaD
Reboxetine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00104	CcSEcCtD
Reboxetine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000172	0.00918	CbGpPWpGaD
Reboxetine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00103	CcSEcCtD
Reboxetine—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000168	0.00901	CbGpPWpGaD
Reboxetine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00102	CcSEcCtD
Reboxetine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00102	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000168	0.00899	CbGpPWpGaD
Reboxetine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000165	0.000996	CcSEcCtD
Reboxetine—SLC6A2—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000164	0.0088	CbGpPWpGaD
Reboxetine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.000993	CcSEcCtD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000164	0.00878	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000163	0.00872	CbGpPWpGaD
Reboxetine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000162	0.00098	CcSEcCtD
Reboxetine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.000977	CcSEcCtD
Reboxetine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000162	0.000977	CcSEcCtD
Reboxetine—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000162	0.00865	CbGpPWpGaD
Reboxetine—Rash—Formoterol—chronic obstructive pulmonary disease	0.00016	0.000969	CcSEcCtD
Reboxetine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00016	0.000969	CcSEcCtD
Reboxetine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00016	0.000968	CcSEcCtD
Reboxetine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00016	0.000968	CcSEcCtD
Reboxetine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000159	0.000963	CcSEcCtD
Reboxetine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000159	0.000963	CcSEcCtD
Reboxetine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000159	0.000963	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000159	0.00852	CbGpPWpGaD
Reboxetine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00096	CcSEcCtD
Reboxetine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00096	CcSEcCtD
Reboxetine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000158	0.000957	CcSEcCtD
Reboxetine—SLC6A2—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000158	0.00845	CbGpPWpGaD
Reboxetine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000157	0.000949	CcSEcCtD
Reboxetine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000157	0.000949	CcSEcCtD
Reboxetine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.000947	CcSEcCtD
Reboxetine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000156	0.000943	CcSEcCtD
Reboxetine—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000155	0.00832	CbGpPWpGaD
Reboxetine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000923	CcSEcCtD
Reboxetine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.00092	CcSEcCtD
Reboxetine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.000917	CcSEcCtD
Reboxetine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.000915	CcSEcCtD
Reboxetine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.000915	CcSEcCtD
Reboxetine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.000914	CcSEcCtD
Reboxetine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000151	0.000913	CcSEcCtD
Reboxetine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000151	0.000913	CcSEcCtD
Reboxetine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000909	CcSEcCtD
Reboxetine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000897	CcSEcCtD
Reboxetine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000148	0.000894	CcSEcCtD
Reboxetine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.000881	CcSEcCtD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000145	0.00778	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000144	0.00773	CbGpPWpGaD
Reboxetine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000867	CcSEcCtD
Reboxetine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.000862	CcSEcCtD
Reboxetine—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000142	0.00762	CbGpPWpGaD
Reboxetine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.000858	CcSEcCtD
Reboxetine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00014	0.00751	CbGpPWpGaD
Reboxetine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000847	CcSEcCtD
Reboxetine—SLC6A4—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000139	0.00742	CbGpPWpGaD
Reboxetine—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000138	0.000837	CcSEcCtD
Reboxetine—SLC6A2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000137	0.00733	CbGpPWpGaD
Reboxetine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000819	CcSEcCtD
Reboxetine—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000135	0.00721	CbGpPWpGaD
Reboxetine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000134	0.000813	CcSEcCtD
Reboxetine—SLC6A2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000134	0.00718	CbGpPWpGaD
Reboxetine—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000133	0.00714	CbGpPWpGaD
Reboxetine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000805	CcSEcCtD
Reboxetine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000796	CcSEcCtD
Reboxetine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000773	CcSEcCtD
Reboxetine—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000128	0.00684	CbGpPWpGaD
Reboxetine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000769	CcSEcCtD
Reboxetine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000753	CcSEcCtD
Reboxetine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000748	CcSEcCtD
Reboxetine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000746	CcSEcCtD
Reboxetine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000741	CcSEcCtD
Reboxetine—SLC6A2—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000119	0.00638	CbGpPWpGaD
Reboxetine—SLC6A4—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000118	0.0063	CbGpPWpGaD
Reboxetine—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000117	0.00628	CbGpPWpGaD
Reboxetine—SLC6A4—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000116	0.00622	CbGpPWpGaD
Reboxetine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000688	CcSEcCtD
Reboxetine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000686	CcSEcCtD
Reboxetine—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000685	CcSEcCtD
Reboxetine—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000113	0.00604	CbGpPWpGaD
Reboxetine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000681	CcSEcCtD
Reboxetine—SLC6A4—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000111	0.00594	CbGpPWpGaD
Reboxetine—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000669	CcSEcCtD
Reboxetine—SLC6A4—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000111	0.00592	CbGpPWpGaD
Reboxetine—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000666	CcSEcCtD
Reboxetine—Syncope—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000665	CcSEcCtD
Reboxetine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000109	0.000661	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000108	0.00579	CbGpPWpGaD
Reboxetine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000652	CcSEcCtD
Reboxetine—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000107	0.00573	CbGpPWpGaD
Reboxetine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00064	CcSEcCtD
Reboxetine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000106	0.00566	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000105	0.00562	CbGpPWpGaD
Reboxetine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000629	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000627	CcSEcCtD
Reboxetine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000624	CcSEcCtD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000103	0.00549	CbGpPWpGaD
Reboxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000103	0.00549	CbGpPWpGaD
Reboxetine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000613	CcSEcCtD
Reboxetine—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000101	0.00542	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000101	0.00542	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	9.99e-05	0.00534	CbGpPWpGaD
Reboxetine—Infection—Prednisone—chronic obstructive pulmonary disease	9.95e-05	0.000601	CcSEcCtD
Reboxetine—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	9.85e-05	0.00527	CbGpPWpGaD
Reboxetine—Shock—Prednisone—chronic obstructive pulmonary disease	9.85e-05	0.000595	CcSEcCtD
Reboxetine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	9.82e-05	0.000593	CcSEcCtD
Reboxetine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	9.77e-05	0.00059	CcSEcCtD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	9.77e-05	0.00523	CbGpPWpGaD
Reboxetine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	9.73e-05	0.000588	CcSEcCtD
Reboxetine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	9.68e-05	0.000585	CcSEcCtD
Reboxetine—Anorexia—Prednisone—chronic obstructive pulmonary disease	9.54e-05	0.000577	CcSEcCtD
Reboxetine—SLC6A2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	9.31e-05	0.00498	CbGpPWpGaD
Reboxetine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.11e-05	0.000551	CcSEcCtD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	9.08e-05	0.00486	CbGpPWpGaD
Reboxetine—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000547	CcSEcCtD
Reboxetine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	8.99e-05	0.000543	CcSEcCtD
Reboxetine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	8.81e-05	0.000533	CcSEcCtD
Reboxetine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.7e-05	0.000526	CcSEcCtD
Reboxetine—Rash—Prednisolone—chronic obstructive pulmonary disease	8.69e-05	0.000525	CcSEcCtD
Reboxetine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.68e-05	0.000524	CcSEcCtD
Reboxetine—Headache—Prednisolone—chronic obstructive pulmonary disease	8.63e-05	0.000522	CcSEcCtD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	8.58e-05	0.00459	CbGpPWpGaD
Reboxetine—Constipation—Prednisone—chronic obstructive pulmonary disease	8.56e-05	0.000517	CcSEcCtD
Reboxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	8.32e-05	0.00445	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	8.3e-05	0.00444	CbGpPWpGaD
Reboxetine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	8.3e-05	0.00444	CbGpPWpGaD
Reboxetine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.25e-05	0.000499	CcSEcCtD
Reboxetine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.19e-05	0.000495	CcSEcCtD
Reboxetine—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.18e-05	0.000495	CcSEcCtD
Reboxetine—Urticaria—Prednisone—chronic obstructive pulmonary disease	7.95e-05	0.000481	CcSEcCtD
Reboxetine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	7.92e-05	0.000478	CcSEcCtD
Reboxetine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	7.92e-05	0.000478	CcSEcCtD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	7.82e-05	0.00419	CbGpPWpGaD
Reboxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.46e-05	0.00399	CbGpPWpGaD
Reboxetine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.38e-05	0.000446	CcSEcCtD
Reboxetine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.36e-05	0.00394	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	7.36e-05	0.00394	CbGpPWpGaD
Reboxetine—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.18e-05	0.000434	CcSEcCtD
Reboxetine—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	7.18e-05	0.00384	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	6.89e-05	0.00369	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	6.86e-05	0.00367	CbGpPWpGaD
Reboxetine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6.85e-05	0.000414	CcSEcCtD
Reboxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	6.71e-05	0.00359	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	6.7e-05	0.00358	CbGpPWpGaD
Reboxetine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	6.62e-05	0.00354	CbGpPWpGaD
Reboxetine—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.62e-05	0.0004	CcSEcCtD
Reboxetine—SLC6A4—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	6.43e-05	0.00344	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	6.4e-05	0.00342	CbGpPWpGaD
Reboxetine—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.37e-05	0.000385	CcSEcCtD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	6.36e-05	0.00341	CbGpPWpGaD
Reboxetine—Rash—Prednisone—chronic obstructive pulmonary disease	6.31e-05	0.000381	CcSEcCtD
Reboxetine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.31e-05	0.000381	CcSEcCtD
Reboxetine—Headache—Prednisone—chronic obstructive pulmonary disease	6.27e-05	0.000379	CcSEcCtD
Reboxetine—HTR2C—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	6.23e-05	0.00333	CbGpPWpGaD
Reboxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.05e-05	0.00323	CbGpPWpGaD
Reboxetine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	6.03e-05	0.00323	CbGpPWpGaD
Reboxetine—Nausea—Prednisone—chronic obstructive pulmonary disease	5.95e-05	0.000359	CcSEcCtD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	5.93e-05	0.00317	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	5.61e-05	0.003	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	5.6e-05	0.003	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	5.57e-05	0.00298	CbGpPWpGaD
Reboxetine—HTR2C—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	5.45e-05	0.00291	CbGpPWpGaD
Reboxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	5.44e-05	0.00291	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	5.41e-05	0.0029	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	5.39e-05	0.00288	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	5.38e-05	0.00288	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.32e-05	0.00285	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.26e-05	0.00281	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	4.99e-05	0.00267	CbGpPWpGaD
Reboxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	4.88e-05	0.00261	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	4.87e-05	0.00261	CbGpPWpGaD
Reboxetine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	4.81e-05	0.00257	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	4.61e-05	0.00247	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	4.59e-05	0.00245	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	4.56e-05	0.00244	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.42e-05	0.00236	CbGpPWpGaD
Reboxetine—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	4.41e-05	0.00236	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.36e-05	0.00233	CbGpPWpGaD
Reboxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	4.21e-05	0.00225	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	4.12e-05	0.00221	CbGpPWpGaD
Reboxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.95e-05	0.00211	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	3.93e-05	0.0021	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.91e-05	0.00209	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.79e-05	0.00203	CbGpPWpGaD
Reboxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.78e-05	0.00202	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.69e-05	0.00197	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	3.66e-05	0.00196	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.64e-05	0.00195	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	3.61e-05	0.00193	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.57e-05	0.00191	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.51e-05	0.00188	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	3.51e-05	0.00188	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.48e-05	0.00186	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.44e-05	0.00184	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	3.43e-05	0.00184	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.39e-05	0.00181	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.34e-05	0.00179	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.21e-05	0.00172	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.2e-05	0.00171	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.17e-05	0.00169	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.17e-05	0.00169	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.15e-05	0.00169	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.14e-05	0.00168	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	2.97e-05	0.00159	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.89e-05	0.00155	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.87e-05	0.00154	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.85e-05	0.00152	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.81e-05	0.0015	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.78e-05	0.00149	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.75e-05	0.00147	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	2.74e-05	0.00147	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	2.73e-05	0.00146	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.58e-05	0.00138	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.57e-05	0.00138	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	2.55e-05	0.00136	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.41e-05	0.00129	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.38e-05	0.00127	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.23e-05	0.00119	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.21e-05	0.00119	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.2e-05	0.00118	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.18e-05	0.00117	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.11e-05	0.00113	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.1e-05	0.00112	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.07e-05	0.00111	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.99e-05	0.00106	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.92e-05	0.00103	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.82e-05	0.000972	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.8e-05	0.000965	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.77e-05	0.000949	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.77e-05	0.000945	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.71e-05	0.000916	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.7e-05	0.000909	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.7e-05	0.000908	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.69e-05	0.000905	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.69e-05	0.000904	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.66e-05	0.000891	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.64e-05	0.000879	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.61e-05	0.000862	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.55e-05	0.000831	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.55e-05	0.000828	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.47e-05	0.000785	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.41e-05	0.000754	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.41e-05	0.000754	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.35e-05	0.000721	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.32e-05	0.000707	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.26e-05	0.000673	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.24e-05	0.000664	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.15e-05	0.000618	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.12e-05	0.000599	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.11e-05	0.000593	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.09e-05	0.000582	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.07e-05	0.00057	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.01e-05	0.000541	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.65e-06	0.000516	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.59e-06	0.000513	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	9.54e-06	0.00051	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.52e-06	0.000509	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.09e-06	0.000487	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	8.99e-06	0.000481	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.71e-06	0.000466	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	8.71e-06	0.000466	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.65e-06	0.000463	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	8.46e-06	0.000453	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.33e-06	0.000446	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	8.2e-06	0.000439	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.02e-06	0.000429	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.74e-06	0.000414	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.56e-06	0.000404	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.69e-06	0.000358	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.6e-06	0.000353	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.37e-06	0.000341	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.3e-06	0.000337	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.22e-06	0.000333	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.15e-06	0.000329	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.07e-06	0.000325	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.95e-06	0.000318	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.88e-06	0.000314	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.83e-06	0.000312	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.8e-06	0.00031	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.79e-06	0.00031	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.49e-06	0.000294	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	5.36e-06	0.000287	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.14e-06	0.000275	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.94e-06	0.000264	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.89e-06	0.000262	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.65e-06	0.000249	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.18e-06	0.000224	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.12e-06	0.000221	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.06e-06	0.000217	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.96e-06	0.000212	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.83e-06	0.000205	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.79e-06	0.000203	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.79e-06	0.000203	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.76e-06	0.000201	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.73e-06	0.0002	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.59e-06	0.000192	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.57e-06	0.000191	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.16e-06	0.000169	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.89e-06	0.000155	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.44e-06	0.000131	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.33e-06	0.000125	CbGpPWpGaD
